The science behind personalised mRNA cancer vaccines

By Maya Shahzad

Intismeran autogene, a bespoke mRNA cancer vaccine developed by Moderna and Merck, is changing how high-risk melanoma is treated. Rather than preventing disease, it is a therapeutic vaccine: given after a melanoma has been surgically removed, it trains the patient’s own immune system to recognise any cancer cells left behind, destroy them and stop the cancer from returning.

The process begins with the tumour itself. Once it is removed, scientists sequence its DNA and compare it with the DNA from the patient’s healthy cells, revealing the mutations. These mutations cause tumour cells to make abnormal proteins called neoantigens, which appear only on cancer cells, acting as ideal flags for the immune system.

A tumour can carry hundreds of mutations, so machine-learning algorithms select the most useful targets. Where possible, they favour clonal mutations, which arise when the first cancer cells form, and are therefore shared by every cell in the tumour, attacking the cancer’s root rather than its branches. The software also predicts how strongly this patient’s immune system will react to each neoantigen, and the 34 highest-scoring are chosen.

Genetic instructions for all 34 neoantigens are written into a single strand of mRNA and, since the body’s enzymes would quickly destroy unprotected mRNA, it is wrapped in lipid nanoparticles, tiny fatty bubbles that help it slip into cells. After rigorous quality checks, the vaccine is injected into the arm muscle every three weeks for up to nine doses. Nearby healthy cells read the mRNA, manufacture the 34 neoantigens and display them on their surface, while the mRNA itself breaks down within days without altering the patient’s DNA.

Patrolling immune cells collect these neoantigens and carry them to the lymph nodes, the immune system’s headquarters, where they train T-cells: white blood cells that hunt down specific threats. Having learned what the neoantigens look like, the T-cells multiply into an army of millions that search the body for any remaining melanoma cells.

Tumours, however, can fight back. By displaying fewer neoantigens on their surface some tumours become increasingly difficult to spot. Others produce a protein called PD-L1, which plugs into an “off switch” (PD-1) on T-cells and shuts the T-cells down before they can attack. This is why the vaccine is given alongside pembrolizumab (Keytruda), an immunotherapy drug that blocks PD-1, so that T-cells stay active. Together, the treatments achieve more than either could alone: the vaccine produces so many trained T-cells that hidden tumour cells are more likely to be found, and pembrolizumab keeps those T-cells switched on.

The results are striking. In the phase 3 INTerpath-001 trial of 1,137 patients, 82.2% of those receiving the combination were alive and recurrence-free after two years, compared with 70.0% on pembrolizumab alone.

This success highlights the importance of personalised treatment. No two melanomas share the same mutations, so no off-the-shelf vaccine could target every patient’s neoantigens; intismeran autogene works because each dose is built from one person’s tumour DNA. This precision makes treatment more effective and, because T-cells target features found only on cancer cells, largely spares healthy tissue. Chemotherapy, by contrast, takes a one-size-fits-all approach that damages any fast-dividing cell, often causing severe side effects. Gentler, targeted treatment can mean a better quality of life during recovery.

Personalised medicine also extends beyond treatment. By reading a patient’s DNA, doctors can identify genetic predispositions to conditions such as heart disease, diabetes or cancer and act before illness develops. As intismeran autogene shows, the future of medicine may lie not in one drug for everyone, but in the right drug for each person.

Howard.R.Pritty via Wikimedia Commons